source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable6 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
locator
title:Cascade-densification deposit: Solanezumab EXPEDITION3 failure (Honig 2018) → broader anti-Aβ MAb scope refinement
imported
2026-05-06T03:57:51.631191+00:00
extraction mode
manual_curation
authors
reviewer:will-blair-bot
Caveats
No source-specific caveats are recorded.
therapeutic · vf_10d9f97f1c08783f
review · vf_3dcfa7fb41b3b39c
therapeutic · vf_b299e3ad7965e4d7
A4 Study (NCT02008357) preclinical solanezumab arm halted 2020 after EXPEDITION3 + multi-cohort futility analysis; preclinical AD as solanezumab indication ruled out alongside mild-AD.
Field consensus 2018-2022 shifted from soluble-Aβ targeting (solanezumab class) to aggregated-Aβ + protofibril targeting (lecanemab, donanemab, aducanumab); EXPEDITION3 read as definitive evidence that soluble Aβ is downstream marker not therapeutic substrate.
DIAN-TU solanezumab arm (dominantly inherited AD prevention) terminated for futility 2020; soluble-Aβ-targeting MAb framework not viable in preclinical AD even in fully penetrant genetic risk.
events
vev_0bb55211bc66258dfinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_327adee886e476e1finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_5aca213c84a622a9finding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_66d0f35c86c36f5cfinding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_94e4e6e8cd0dfa0dfinding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_cbd0279e6a68f029finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_12931a6601a7c828finding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_19efd08ab5224ffcfinding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_1cdb7be6b81b9c26finding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_243c0195a9f529aefinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_572854aaebd2536ffinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_fb13d9c46980221cfinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation rows are attached.